Morepen Laboratories Ltd Q3 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/gseevzs723khms0c6ok3q8rk.pdf

Key Takeaways


China Price Cycle & API Margin Dynamics

Sushil Suri: "The way I look at it that okay these margin profile is temporary because prices in B2B things come up and down very fast and frequent. So, because one supplier changes one price and our whole costing goes up and down. That doesn't mean that the margin has gone down or up."

Medical Devices: The Growth Engine

Sushil Suri: "I am seeing at least for another 10 years, we are seeing an open platform, open canvas and the story would be written year-after-year and coupled with the technology, thanks to mobile then connected devices and telemedicine. So, this is a place where we will be there for life."

Export Markets: Europe Surges, US Stalls

Sushil Suri: "Rs. 500 crore export in nine months itself is a landmark. So, we never had a Rs. 500 crore export in nine months. So, this itself is the highest ever in the Morepen history."

Capacity Build-Out & Product Pipeline


The Margin Roadmap: From API to Formulations

Sushil Suri: "If I convert that API into formulation, so I got 10x revenue. Of course, I have to do a little more effort to convert it and to get approval. So, if I jumble up, finished dosage, the API cost is only 10%. Instead of selling API for $100, if I make a formulation, it will sell for $1,000."

Guidance & Commitments

CommitmentSpecificsTimeline
Full-year EPSRs. 2.5 (TTM currently 2.39)FY25
Pharma revenueRs. 1,150–1,200 croresFY25
Medical devices revenueRs. 470–475 croresFY25
Total exportsCrossing Rs. 650–700 croresFY25
API capacityAll 600 KL ready for executionWithin 6–9 months
Revenue growth10–15% bare minimum; higher if China prices stabilizeOngoing
Long-term CAGR20%Long term
Formulation + OTC growthAt least 25%Ongoing
Near-term EBITDA margin11–12%While formulation share is still small (1–2 years)
Long-term EBITDA margin15%, driven by finished dosage mix shift and devices exportLong term
Medical devices export contributionStart contributing12–18 months
Finished dosage exportStart2–3 years
CDMO scientific labMay come upAbout one year ("still not on the cards")

Key Metrics

MetricQ3 FY25
Revenue (quarterly)₹458 cr, up 2% YoY from ₹449 cr
Revenue (nine months)₹1,359 cr, up 6.5% YoY from ₹1,277 cr
EBITDA (quarterly)₹41 cr, down 24% YoY; margin 9.05% vs 12% last year
EBITDA (nine months)up 21% YoY; margin 10.71% vs ~10% last year
Profit after tax (quarterly)₹27 cr, vs ₹34 cr in Q3 FY24
Profit after tax (nine months)₹97.71 cr, up 44% YoY; exceeds full FY24 PAT of ₹96 cr
EPS (quarterly)₹0.49
EPS (trailing 12 months)₹2.39, targeting ₹2.5 for full year
Pharma segment revenue (quarterly)₹335 cr; nine months ₹966 cr
Medical devices revenue (quarterly)₹123 cr, up 15% YoY from ₹107 cr; nine months ₹394 cr, up 11% YoY
Medical devices share of total revenue29% for nine months, up from 26% last year
Exports (nine months)₹500 cr, up 10% YoY; highest ever for nine months
API business growth (nine months)3.6% YoY; quantity sold up 11% to 341 MT
Rx and OTC business growth (nine months)8% YoY
Glucometer installed base1.35 cr meters, up from 1.16 cr in March 2024
Glucometer strips sold (nine months)33 cr strips; last full year 36 cr
BP monitor installed base0.67 cr meters
BP monitors sold (nine months)9.5 lakh units, up from 8.48 lakh last year
US market revenue (nine months)₹102 cr, down 14% YoY from ₹119 cr
Europe market revenue (nine months)₹151 cr, up 55% YoY from ₹97 cr
API capacity510 KL operational; total planned 600 KL per QIP
FY25 estimated revenue~₹1,900 cr, ~7% growth (per an analyst's math; management noted 10-11% growth but not official guidance)